Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 2,538 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parasomnia Clear all
Completed Phase 2 Interventional

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

NCT05423717
View directory record Official record
Conditions
Insomnia
Interventions
Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
10 Years to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
12
States / cities
Tucson, Arizona • Little Rock, Arkansas • Brandon, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Terminated Phase 4 Interventional

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

NCT02117076
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
Gabapentin immediate release, Gabapentin enacarbil extended release
Drug
Lead sponsor
Theresa Zesiewicz, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

NCT05156047
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Open-label Pitolisant, Double-blind Placebo, Double-blind Pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
58
States / cities
Peoria, Arizona • Scottsdale, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Completed No phase listed Observational Results available

Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)

NCT00354614
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
ApneaLink Sleep Screener
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Nov 1, 2026, 1:29 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vascular Pathophysiology in Obstructive Sleep Apnea

NCT00214084
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Allopurinol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Nov 1, 2026, 1:29 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)

NCT07823608
View directory record Official record
Conditions
Apnea, Sleep Disorders, Overweight and/or Obesity
Interventions
Berobenatide, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Cullman, Alabama • Riverside, California • Bradenton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

NCT00940589
View directory record Official record
Conditions
Alzheimer's Disease, Sleep Disorder
Interventions
Circadin, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Brooksville, Florida • St. Petersburg, Florida • Mount Arlington, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Nov 1, 2026, 1:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Non-Invasive At-Home Sleep Therapy System

NCT05970276
View directory record Official record
Conditions
Sleep, Sleep Duration, Sleep Quality
Interventions
Deep Sleep (N3) Enhancement with TES
Device
Lead sponsor
Brain Electrophysiology Laboratory Company
Industry
Eligibility
22 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Nov 1, 2026, 1:29 AM EDT
Active, not recruiting No phase listed Observational

Impact of GABA Probiotic Lactiplantibacillus Plantarum Lp815 on Sleep Outcomes in Participants with Self-Reported Sleep Disturbance

NCT06789718
View directory record Official record
Conditions
Insomnia (moderate)
Interventions
GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose), Placebo, Optional Sub-Study: Neurotransmitter Urine Test
Dietary Supplement · Other · Diagnostic Test
Lead sponsor
Verb Biotics LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

NCT05472090
View directory record Official record
Conditions
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
Interventions
TNX-102 SL, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Oceanside, California • Santa Ana, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug

NCT04299490
View directory record Official record
Conditions
Sleep Disorder, Healthy
Interventions
Sleep Fragmentation, Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo), Sleep Continuity Disruption, Undisturbed Sleep
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 48 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer

NCT02609880
View directory record Official record
Conditions
Genital Neoplasms, Female, Insomnia, Pain, Adaptation, Psychological
Interventions
Cognitive Behavioral Therapy, Psychoeducation
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Not applicable Interventional Results available

Adherence to Electrical Glossal In Situ Stimulation for Sleep Apnea (AEGIS Study)

NCT04974515
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
eXciteOSA
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Combined Blue and Red Home-Based Light Therapy on Sleep in Adults With Self-Reported Sleep Difficulties

NCT07465250
View directory record Official record
Conditions
Sleep
Interventions
LED portable light therapy bulb
Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Terminated Not applicable Interventional

Effect of Holofiber Socks and Bedding on Pain and Quality of Sleep in Subjects With Chronic Foot Pain

NCT00458497
View directory record Official record
Conditions
Diabetic Neuropathy, Arthritis, Peripheral Arterial Disease, Plantar Fasciitis
Interventions
Holofiber fabric, PET fabric
Device
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2010 · Synced Nov 1, 2026, 1:29 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Start Times and Restful Sleep

NCT04049682
View directory record Official record
Conditions
Excessive Daytime Somnolence, Sleep Deprivation
Interventions
Delayed School Start Time
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
13 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Not applicable Interventional Results available

CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes

NCT02535923
View directory record Official record
Conditions
Insomnia, Psychosis
Interventions
Cognitive Behavioral Therapy-Insomnia, Health and Wellness
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations

NCT01673880
View directory record Official record
Conditions
Insomnia
Interventions
E2006
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

NCT01624480
View directory record Official record
Conditions
Narcolepsy
Interventions
Armodafinil
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 1, 2026, 1:29 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Impacts of Opioids on Respiratory Drive During Sleep

NCT06854211
View directory record Official record
Conditions
Opioids, Obstructive Sleep Apnea (OSA)
Interventions
Morphine p.o., Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Not applicable Interventional Results available

Investigating the Experience of Living With Down Syndrome and Obstructive Sleep Apnea Syndrome (Stage 1)

NCT04124471
View directory record Official record
Conditions
Down Syndrome, Obstructive Sleep Apnea
Interventions
Open-ended semi-structured interviews
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Nov 1, 2026, 1:29 AM EDT
Not yet recruiting Phase 2 Interventional

Daridorexant for People With Insomnia and Alcohol Use Disorder Study

NCT07701928
View directory record Official record
Conditions
Alcohol Use Disorder, Insomnia
Interventions
Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence
Drug · Behavioral · Device
Lead sponsor
Sterling McPherson
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Feasibility and Acceptability of an Internet-based Cognitive-behavioral Treatment for Insomnia in Adults With Asthma

NCT03002402
View directory record Official record
Conditions
Asthma, Insomnia Chronic
Interventions
Internet-based CBT-I
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Nov 1, 2026, 1:29 AM EDT
Terminated No phase listed Observational

Obesity Hypoventilation Syndrome Prevalence Study

NCT01964339
View directory record Official record
Conditions
Obesity Hypoventilation Syndrome
Interventions
BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study., BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
Other
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Nov 1, 2026, 1:29 AM EDT